Minerva Neurosciences, Inc (NERV): Price and Financial Metrics


Minerva Neurosciences, Inc (NERV): $1.69

0.10 (+6.29%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add NERV to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

NERV Stock Price Chart Interactive Chart >

Price chart for NERV

NERV Price/Volume Stats

Current price $1.69 52-week high $15.27
Prev. close $1.59 52-week low $1.26
Day low $1.56 Volume 25,800
Day high $1.70 Avg. volume 84,543
50-day MA $2.17 Dividend yield N/A
200-day MA $4.13 Market Cap 9.02M

Minerva Neurosciences, Inc (NERV) Company Bio


Minerva Neurosciences, Inc. focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. The company was founded in 2007 and is based in Waltham, Massachusetts.


NERV Latest News Stream


Event/Time News Detail
Loading, please wait...

NERV Latest Social Stream


Loading social stream, please wait...

View Full NERV Social Stream

Latest NERV News From Around the Web

Below are the latest news stories about MINERVA NEUROSCIENCES INC that investors may wish to consider to help them evaluate NERV as an investment opportunity.

Minerva Neurosciences, Inc. (NASDAQ:NERV) Q4 2022 Earnings Call Transcript

Minerva Neurosciences, Inc. (NASDAQ:NERV) Q4 2022 Earnings Call Transcript March 8, 2023 Operator: Good day, and thank you for standing by. Welcome to Minerva Neurosciences Full Year 2022 Financial Results and Business Update Conference Call. Please be advised that today’s conference is being recorded. I would now like to hand the conference over to your […]

Yahoo | March 10, 2023

Q4 2022 Minerva Neurosciences Inc Earnings Call

Q4 2022 Minerva Neurosciences Inc Earnings Call

Yahoo | March 9, 2023

Minerva Neurosciences Reports Fiscal Year 2022 Fourth Quarter And Year End Financial Results And Business Updates

Company to Host Conference Call Today at 8:30 a.m. ETBURLINGTON, Mass., March 08, 2023 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today reported business updates and financial results for the fourth quarter and year ended December 31, 2022. Corporate Update “In 2022, we had multiple interactions with the FDA regarding the regulatory path forward for o

Yahoo | March 8, 2023

Minerva Neurosciences to Report Fiscal Year 2022 Financial Results and Business Updates on March 8, 2023

Management to Host Conference CallBURLINGTON, Mass., March 01, 2023 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will release fiscal year 2022 financial results and business updates on Wednesday, March 8, 2023. The Company will host a webcast that day at 8:30 a.m. Eastern Time to discuss the results and updates. The live co

Yahoo | March 1, 2023

Minerva (NERV) Down; FDA Denies Review Schizophrenia Drug NDA

Minerva (NERV) confirmed that the FDA's refuse-to-file letter on its regulatory filing, seeking approval for roluperidone, to treat symptoms of schizophrenia remains in effect.

Yahoo | December 29, 2022

Read More 'NERV' Stories Here

NERV Price Returns

1-mo N/A
3-mo -33.98%
6-mo -81.89%
1-year -73.44%
3-year -95.69%
5-year -96.70%
YTD 6.29%
2022 -75.19%
2021 -65.77%
2020 -67.09%
2019 5.49%
2018 11.40%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7495 seconds.